Theseus Pharmaceuticals, Inc.
Theseus Pharmaceuticals, Inc. (THRX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · THRX · as of Jun 9, 2026
Activity summary
Buy transactions
6
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Theseus Pharmaceuticals, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
THRX insider buying and selling by quarter
THRX insider selling · THRX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
THRX executive sell shares · THRX board member insider trading · THRX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Feb 14, 2024 | ORBIMED ADVISORS LLC Director | Other | 650,600 | $2.63M⚡ | Form 4 |
| Feb 14, 2024 | HAYDEN DONALD J JR Director | Other | 10,000 | $41K | Form 4 |
| Feb 14, 2024 | GORDON CARL L Director | Other | 650,600 | $2.63M⚡ | Form 4 |
| Feb 14, 2024 | Dukes Iain D. Director | Other | 388,324 | $1.57M⚡ | Form 4 |
| Feb 14, 2024 | Dahms Bradford D. President and CFO | Other | 8,150.225 | $33K | Form 4 |
| Nov 6, 2023 | Shakespeare William See Remarks | Option | 251,084 | $80K | Form 4 |
| Jul 17, 2023 | GORDON CARL L Director | Purchase | 328,482 | $1.00M⚡ | Form 4 |
| Jul 17, 2023 | GORDON CARL L Director | Purchase | 151,450 | $462K | Form 4 |
| Jul 17, 2023 | ORBIMED ADVISORS LLC Director | Purchase | 328,482 | $1.00M⚡ | Form 4 |
| Jul 17, 2023 | ORBIMED ADVISORS LLC Director | Purchase | 151,450 | $462K | Form 4 |
| Jul 17, 2023 | Foresite Capital Management V, LLC 10 percent owner | Purchase | 523,450 | $1.55M⚡ | Form 4 |
| Jul 17, 2023 | Foresite Capital Management V, LLC 10 percent owner | Purchase | 176,550 | $524K | Form 4 |
| Dec 29, 2022 | Foresite Capital Management V, LLC Director | Purchase | 250,000 | $1.25M⚡ | Form 4 |
| Dec 29, 2022 | Foresite Capital Management V, LLC Director | Purchase | 250,000 | $1.25M⚡ | Form 4 |
| Dec 30, 2022 | HAYDEN DONALD J JR Director | Purchase | 9,900 | $49K | Form 4 |
| Dec 29, 2022 | HAYDEN DONALD J JR Director | Purchase | 100 | $500 | Form 4 |
| Nov 30, 2022 | Dahms Bradford D. CFO | Purchase | 1,502.189 | $10K | Form 4 |
| Nov 11, 2022 | CLACKSON TIMOTHY P President and CEO | Purchase | 2,500 | $17K | Form 4 |
| Nov 7, 2022 | GORDON CARL L Director | Purchase | 192,000 | $1.00M⚡ | Form 4 |
| Nov 7, 2022 | ORBIMED ADVISORS LLC Director | Purchase | 192,000 | $1.00M⚡ | Form 4 |
| Jan 21, 2022 | GORDON CARL L Director | Purchase | 111,896 | $1.12M⚡ | Form 4 |
| Jan 20, 2022 | GORDON CARL L Director | Purchase | 35,000 | $348K | Form 4 |
| Jan 19, 2022 | GORDON CARL L Director | Purchase | 11,521 | $115K | Form 4 |
| Jan 21, 2022 | ORBIMED ADVISORS LLC Director | Purchase | 111,896 | $1.12M⚡ | Form 4 |
| Jan 20, 2022 | ORBIMED ADVISORS LLC Director | Purchase | 35,000 | $348K | Form 4 |
ORBIMED ADVISORS LLC
Director
Date
Feb 14
Shares
650,600
Price
$4.05
Value
$2.63M ⚡
Dahms Bradford D.
President and CFO
Date
Feb 14
Shares
8,150.225
Price
$4.05
Value
$33K
ORBIMED ADVISORS LLC
Director
Date
Jul 17
Shares
328,482
Price
$3.05
Value
$1.00M ⚡
ORBIMED ADVISORS LLC
Director
Date
Jul 17
Shares
151,450
Price
$3.05
Value
$462K
Foresite Capital Management V, LLC
10 percent owner
Date
Jul 17
Shares
523,450
Price
$2.97
Value
$1.55M ⚡
Foresite Capital Management V, LLC
10 percent owner
Date
Jul 17
Shares
176,550
Price
$2.97
Value
$524K
Foresite Capital Management V, LLC
Director
Date
Dec 29
Shares
250,000
Price
$5.00
Value
$1.25M ⚡
Foresite Capital Management V, LLC
Director
Date
Dec 29
Shares
250,000
Price
$5.00
Value
$1.25M ⚡
CLACKSON TIMOTHY P
President and CEO
Date
Nov 11
Shares
2,500
Price
$6.80
Value
$17K
ORBIMED ADVISORS LLC
Director
Date
Nov 7
Shares
192,000
Price
$5.21
Value
$1.00M ⚡
ORBIMED ADVISORS LLC
Director
Date
Jan 21
Shares
111,896
Price
$9.97
Value
$1.12M ⚡
ORBIMED ADVISORS LLC
Director
Date
Jan 20
Shares
35,000
Price
$9.95
Value
$348K
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About THRX insider trading
THRX insider trades
Theseus Pharmaceuticals, Inc. (THRX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including THRX. Over the past 12 months, 0 insiders have filed transactions with the SEC. THRX insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Theseus Pharmaceuticals, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
THRX insider trading · 5 questionsThe insiders of Theseus Pharmaceuticals, Inc. (THRX) include executives and directors such as THRX, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026